s6y

MiNK Therapeutics, Inc.

Ticker
INKT
CIK
1840229
Industry
Biological Products, (No Diagnostic Substances)
Formerly
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.

Financials 21

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 21 financials filings

News 43

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 43 news filings

Ownership 151

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 151 ownership filings

Prospectus 21

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-3/A Registration statement for specified transactions by certain issuers
  3. S-3 Registration statement for specified transactions by certain issuers
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 21 prospectus filings

Proxies 8

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. DEF 14A Definitive proxy statements
  8. DEF 14A Definitive proxy statements

Other 23

  1. 144 Filing for proposed sale of securities under Rule 144
  2. ARS Annual report to security holders
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. 144 Filing for proposed sale of securities under Rule 144
  6. ARS Annual report to security holders
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. ARS Annual report to security holders

All 23 other filings